iCAD Stock Price, News & Analysis (NASDAQ:ICAD)

$3.66 0.01 (0.27 %)
(As of 12/17/2017 06:55 AM ET)
Previous Close$3.66
Today's Range$3.65 - $3.78
52-Week Range$3.13 - $6.07
Volume17,551 shs
Average Volume23,613 shs
Market Capitalization$60.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51

About iCAD (NASDAQ:ICAD)

iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.

Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Computer Peripherals
Sub-IndustryN/A
SectorComputer and Technology
SymbolNASDAQ:ICAD
CUSIPN/A
Phone603-882-5200

Debt

Debt-to-Equity Ratio0.31%
Current Ratio1.95%
Quick Ratio1.67%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.34 million
Price / Sales2.29
Cash FlowN/A
Price / CashN/A
Book Value$1.56 per share
Price / Book2.35

Profitability

Trailing EPS($0.81)
Net Income$-10,090,000.00
Net Margins-49.16%
Return on Equity-47.31%
Return on Assets-29.64%

Miscellaneous

Employees118
Outstanding Shares16,510,000

iCAD (NASDAQ:ICAD) Frequently Asked Questions

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

How were iCAD's earnings last quarter?

iCAD Inc (NASDAQ:ICAD) issued its earnings results on Wednesday, November, 8th. The technology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. The technology company had revenue of $7 million for the quarter, compared to analyst estimates of $7.43 million. iCAD had a negative net margin of 49.16% and a negative return on equity of 47.31%. View iCAD's Earnings History.

When will iCAD make its next earnings announcement?

iCAD is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for iCAD.

Where is iCAD's stock going? Where will iCAD's stock price be in 2017?

1 brokerages have issued 12-month price targets for iCAD's shares. Their forecasts range from $11.00 to $11.00. On average, they expect iCAD's stock price to reach $11.00 in the next twelve months. View Analyst Ratings for iCAD.

Who are some of iCAD's key competitors?

Who are iCAD's key executives?

iCAD's management team includes the folowing people:

  • Lawrence Howard, Chairman of the Board (Age 63)
  • Kenneth M. Ferry, Chief Executive Officer, Director (Age 61)
  • Richard C. Christopher, Chief Financial Officer, Executive Vice President (Age 46)
  • Stacey M. Stevens, Senior Vice President - Marketing and Strategy (Age 48)
  • Jonathan Go, Senior Vice President - Research and Development (Age 52)
  • R. Scott Areglado, Vice President, Corporate Controller
  • Andrew Heroux Sassine, Director (Age 52)
  • Rachel Brem M.D., Independent Director (Age 56)
  • Anthony F. Ecock, Independent Director (Age 53)
  • Robert L. Goodman M.D., Independent Director (Age 74)

Who owns iCAD stock?

iCAD's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Granite Investment Partners LLC (1.38%), Dimensional Fund Advisors LP (0.54%) and Segall Bryant & Hamill LLC (0.18%). Company insiders that own iCAD stock include Dr Lawrence Howard, Kenneth M Ferry and Kevin C Burns. View Institutional Ownership Trends for iCAD.

Who sold iCAD stock? Who is selling iCAD stock?

iCAD's stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC. View Insider Buying and Selling for iCAD.

Who bought iCAD stock? Who is buying iCAD stock?

iCAD's stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP and Segall Bryant & Hamill LLC. Company insiders that have bought iCAD stock in the last two years include Dr Lawrence Howard, Kenneth M Ferry and Kevin C Burns. View Insider Buying and Selling for iCAD.

How do I buy iCAD stock?

Shares of iCAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is iCAD's stock price today?

One share of iCAD stock can currently be purchased for approximately $3.66.

How big of a company is iCAD?

iCAD has a market capitalization of $60.43 million and generates $26.34 million in revenue each year. The technology company earns $-10,090,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. iCAD employs 118 workers across the globe.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]


MarketBeat Community Rating for iCAD (ICAD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  37 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  75
MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

iCAD (NASDAQ:ICAD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.00$11.00$11.00N/A
Price Target Upside: 179.19% upside179.19% upside179.19% upsideN/A

iCAD (NASDAQ:ICAD) Consensus Price Target History

Price Target History for iCAD (NASDAQ:ICAD)

iCAD (NASDAQ:ICAD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/25/2017LaidlawReiterated RatingBuy$11.00MediumView Rating Details
(Data available from 12/17/2015 forward)

Earnings

iCAD (NASDAQ:ICAD) Earnings History and Estimates Chart

Earnings by Quarter for iCAD (NASDAQ:ICAD)

iCAD (NASDAQ ICAD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018        
11/8/2017Q3 2017($0.14)($0.13)$7.43 million$7.00 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.19)($0.16)$6.41 million$6.41 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.20)($0.18)$6.40 million$6.79 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.17)($0.20)$6.60 million$6.93 millionViewListenView Earnings Details
11/2/2016Q3 2016($0.14)($0.16)$7.44 million$6.00 millionViewN/AView Earnings Details
7/27/2016Q2($0.14)($0.09)$6.99 million$7.37 millionViewListenView Earnings Details
5/3/2016Q1($0.14)($0.17)$7.27 million$6.04 millionViewN/AView Earnings Details
3/1/2016Q4($0.17)($0.14)$7.77 million$7.61 millionViewN/AView Earnings Details
10/29/2015Q315($0.07)($0.03)$8.09 million$9.58 millionViewListenView Earnings Details
2/24/2015Q414$0.04$0.01$13.30 million$13.20 millionViewN/AView Earnings Details
7/30/2014Q2 2014($0.02)($0.04)$9.02 million$9.67 millionViewN/AView Earnings Details
5/6/2014Q1($0.15)($0.12)$7.95 million$8.50 millionViewListenView Earnings Details
2/19/2014Q4($0.17)($0.41)$8.25 million$9.14 millionViewListenView Earnings Details
10/29/2013Q313($0.20)($0.11)$8.07 million$8.30 millionViewListenView Earnings Details
7/29/2013Q2 2013($0.25)($0.12)$7.56 million$7.71 millionViewListenView Earnings Details
2/19/2013Q4 2012($0.15)$6.61 million$7.82 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

iCAD (NASDAQ:ICAD) Earnings Estimates

2017 EPS Consensus Estimate: ($0.62)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.19)($0.19)($0.19)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.14)($0.14)($0.14)
Q4 20171($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for iCAD (NASDAQ:ICAD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

iCAD (NASDAQ ICAD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.20%
Institutional Ownership Percentage: 21.98%
Insider Trades by Quarter for iCAD (NASDAQ:ICAD)
Insider Trades by Quarter for iCAD (NASDAQ:ICAD)

iCAD (NASDAQ ICAD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/23/2017Dr Lawrence HowardDirectorBuy10,000$3.33$33,300.00View SEC Filing  
11/14/2016Kenneth M FerryCEOBuy10,000$3.50$35,000.00View SEC Filing  
3/4/2016Kenneth M FerryCEOBuy25,000$4.45$111,250.00View SEC Filing  
3/4/2016Kevin C BurnsCFOBuy10,000$4.44$44,400.00View SEC Filing  
3/19/2015Kenneth M FerryCEOSell100,000$10.00$1,000,000.00View SEC Filing  
3/12/2015Somu SubramaniamDirectorSell50,762$9.23$468,533.26View SEC Filing  
2/10/2015Stacey M StevensSVPSell27,298$10.00$272,980.00View SEC Filing  
12/3/2014Stacey M StevensSVPSell2,502$10.00$25,020.00View SEC Filing  
12/2/2014Stacey M StevensSVPSell503$10.01$5,035.03View SEC Filing  
12/1/2014Stacey M StevensSVPSell299$10.00$2,990.00View SEC Filing  
11/11/2014Kenneth M FerryCEOSell18,318$11.09$203,146.62View SEC Filing  
11/3/2014Stacey M StevensVPSell10,000$11.31$113,100.00View SEC Filing  
10/1/2014Stacey M StevensVPSell13,333$10.00$133,330.00View SEC Filing  
9/3/2014Stacey M StevensVPSell10,000$10.94$109,400.00View SEC Filing  
8/27/2014Kevin C BurnsCFOSell36,439$10.44$380,423.16View SEC Filing  
8/25/2014Kenneth M FerryCEOSell40,000$10.71$428,400.00View SEC Filing  
8/20/2014Stacey M StevensVPSell5,000$10.57$52,850.00View SEC Filing  
8/19/2014Kenneth M FerryCEOSell20,000$10.06$201,200.00View SEC Filing  
8/26/2013Kenneth M FerryCEOBuy5,000$5.55$27,750.00View SEC Filing  
5/3/2013Kevin C BurnsCFOBuy2,900$5.19$15,051.00View SEC Filing  
8/24/2012Kevin C BurnsCFOBuy15,000$2.08$31,200.00View SEC Filing  
8/17/2012Kevin C BurnsCFOBuy28,939$2.90$83,923.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

iCAD (NASDAQ ICAD) News Headlines

Source:
DateHeadline
ICAD: Study Shows IORT Superior To EBRT in Quality of Life, CostICAD: Study Shows IORT Superior To EBRT in Quality of Life, Cost
finance.yahoo.com - December 15 at 11:47 AM
Two Centers from The US Oncology Network Adopt iCAD’s Xoft Electronic Brachytherapy System for Treatment of Early-Stage Non-Melanoma Skin CancerTwo Centers from The US Oncology Network Adopt iCAD’s Xoft Electronic Brachytherapy System for Treatment of Early-Stage Non-Melanoma Skin Cancer
finance.yahoo.com - December 12 at 11:56 AM
iCAD Announces Study Demonstrating Economic and Health Benefits of Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer TreatmentiCAD Announces Study Demonstrating Economic and Health Benefits of Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer Treatment
finance.yahoo.com - December 7 at 11:47 AM
iCAD’s PowerLook® Tomo Detection Experiences Growing AdoptioniCAD’s PowerLook® Tomo Detection Experiences Growing Adoption
finance.yahoo.com - November 27 at 5:25 PM
Are iCAD Inc’s (ICAD) Interest Costs Too High?Are iCAD Inc’s (ICAD) Interest Costs Too High?
finance.yahoo.com - November 22 at 12:54 AM
ICAD: Q3 Detection and Therapy Results Solid. Tomo Growth To AccelerateICAD: Q3 Detection and Therapy Results Solid. Tomo Growth To Accelerate
finance.yahoo.com - November 13 at 7:45 PM
Edited Transcript of ICAD earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of ICAD earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 11 at 10:46 AM
iCAD Announces Positive Clinical Data on Xoft System for Non-Melanoma Skin Cancer Treatment Selected as “Best of ASTRO 2017”iCAD Announces Positive Clinical Data on Xoft System for Non-Melanoma Skin Cancer Treatment Selected as “Best of ASTRO 2017”
finance.yahoo.com - November 11 at 10:46 AM
icad inc. (ICAD) Issues  Earnings Resultsicad inc. (ICAD) Issues Earnings Results
www.americanbankingnews.com - November 9 at 7:48 PM
Icad reports 3Q lossIcad reports 3Q loss
www.cnbc.com - November 9 at 2:35 AM
Imaging For Women Now Offering ICADs PowerLook® Tomo Detection For Digital Breast TomosynthesisImaging For Women Now Offering ICAD's PowerLook® Tomo Detection For Digital Breast Tomosynthesis
www.thestreet.com - November 8 at 4:32 PM
iCAD, Inc. to Host Earnings CalliCAD, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 4:32 PM
iCAD Reports Third Quarter 2017 Financial ResultsiCAD Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 4:32 PM
Imaging for Women Now Offering iCAD’s PowerLook® Tomo Detection for Digital Breast TomosynthesisImaging for Women Now Offering iCAD’s PowerLook® Tomo Detection for Digital Breast Tomosynthesis
finance.yahoo.com - November 8 at 10:05 AM
The global brachytherapy market is expected to reach USD 486.9 million by 2025The global brachytherapy market is expected to reach USD 486.9 million by 2025
finance.yahoo.com - November 3 at 8:26 AM
icad inc. (ICAD) Scheduled to Post Earnings on Wednesdayicad inc. (ICAD) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - November 2 at 9:53 AM
iCAD to Report Third Quarter 2017 Financial Results on Wednesday, November 8iCAD to Report Third Quarter 2017 Financial Results on Wednesday, November 8
finance.yahoo.com - November 2 at 1:57 AM
iCAD’s PowerLook Tomo Detection for Digital Breast Tomosynthesis Named 2017 Product of the Year by New Hampshire High Technology CounciliCAD’s PowerLook Tomo Detection for Digital Breast Tomosynthesis Named 2017 Product of the Year by New Hampshire High Technology Council
finance.yahoo.com - October 26 at 12:40 PM
iCAD Announces Presentation of New Clinical Data on Xoft System for Treatment of Nonmelanoma Skin Cancer and Early-Stage Breast Cancer at ASTRO 2017iCAD Announces Presentation of New Clinical Data on Xoft System for Treatment of Nonmelanoma Skin Cancer and Early-Stage Breast Cancer at ASTRO 2017
finance.yahoo.com - September 25 at 9:54 AM
iCAD to Present at the Cantor Fitzgerald Global Healthcare ConferenceiCAD to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 4:05 PM
Tech PR Agency ARPR Adds Two Marquee Health IT Brands to Its Portfolio; Erin Bocherer Hired as First Practice Group DirectorTech PR Agency ARPR Adds Two Marquee Health IT Brands to Its Portfolio; Erin Bocherer Hired as First Practice Group Director
www.marketwatch.com - September 14 at 11:31 PM
ETFs with exposure to iCAD, Inc. : September 6, 2017ETFs with exposure to iCAD, Inc. : September 6, 2017
finance.yahoo.com - September 6 at 6:15 AM
iCAD, Inc. :ICAD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 31, 2017iCAD, Inc. :ICAD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 31, 2017
finance.yahoo.com - August 31 at 7:43 PM
BRIEF-ICAD Inc ‍announces approval of Xoft Axxent balloon applicators by China FDABRIEF-ICAD Inc ‍announces approval of Xoft Axxent balloon applicators by China FDA
www.reuters.com - August 31 at 6:00 AM
iCAD Announces Approval of Xoft® Axxent® Balloon Applicators by China Food & Drug Administration for Treatment of Early-Stage Breast CanceriCAD Announces Approval of Xoft® Axxent® Balloon Applicators by China Food & Drug Administration for Treatment of Early-Stage Breast Cancer
finance.yahoo.com - August 31 at 6:00 AM
icad inc. (ICAD) Director Acquires $33,300.00 in Stockicad inc. (ICAD) Director Acquires $33,300.00 in Stock
www.americanbankingnews.com - August 24 at 4:30 PM
icad inc. (ICAD) Expected to Earn FY2019 Earnings of $0.03 Per Shareicad inc. (ICAD) Expected to Earn FY2019 Earnings of $0.03 Per Share
www.americanbankingnews.com - August 18 at 2:08 PM
ICAD: A Look Behind Q2 Numbers. U.S. Tomo Launch EncouragingICAD: A Look Behind Q2 Numbers. U.S. Tomo Launch Encouraging
finance.yahoo.com - August 18 at 5:09 AM
Edited Transcript of ICAD earnings conference call or presentation 8-Aug-17 8:30pm GMTEdited Transcript of ICAD earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 5:29 AM
icad inc. (NASDAQ:ICAD) Issues Quarterly  Earnings Resultsicad inc. (NASDAQ:ICAD) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 9:30 PM
iCAD Reports Second Quarter 2017 Financial Results and Announces $13 Million Credit Facility With Silicon Valley BankiCAD Reports Second Quarter 2017 Financial Results and Announces $13 Million Credit Facility With Silicon Valley Bank
finance.yahoo.com - August 8 at 7:24 PM
icad inc. (ICAD) to Release Earnings on Tuesdayicad inc. (ICAD) to Release Earnings on Tuesday
www.americanbankingnews.com - August 3 at 10:58 AM
iCAD to Present at the Canaccord Genuity 37th Annual Growth ConferenceiCAD to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 1 at 3:18 PM
iCAD to Report Second Quarter 2017 Financial Results on Tuesday, August 8iCAD to Report Second Quarter 2017 Financial Results on Tuesday, August 8
finance.yahoo.com - July 31 at 7:10 PM
Researchers to Present Clinical Data Supporting Use of Xoft System for Endometrial Cancer Treatment at American Association of Physicists in Medicine Annual Meeting & ExhibitionResearchers to Present Clinical Data Supporting Use of Xoft System for Endometrial Cancer Treatment at American Association of Physicists in Medicine Annual Meeting & Exhibition
finance.yahoo.com - July 27 at 10:08 PM
iCAD announces positive study results comparing use of company’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® to Mohs surgery in treatment of early-stage non-melanoma skin canceriCAD announces positive study results comparing use of company’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® to Mohs surgery in treatment of early-stage non-melanoma skin cancer
finance.yahoo.com - July 25 at 8:02 PM
Preliminary results show targeted treatment offers low toxicity for patients with endometrial or cervical cancerPreliminary results show targeted treatment offers low toxicity for patients with endometrial or cervical cancer
www.nasdaq.com - May 5 at 5:49 PM
Icad reports 1Q lossIcad reports 1Q loss
www.cnbc.com - May 3 at 5:37 PM
iCAD to Report First Quarter 2017 Financial Results on Tuesday, May 2iCAD to Report First Quarter 2017 Financial Results on Tuesday, May 2
feeds.benzinga.com - April 24 at 8:28 AM
iCAD Cancer Detecting Product Gets FDA Premarket OK (ICAD)iCAD Cancer Detecting Product Gets FDA Premarket OK (ICAD)
www.investopedia.com - March 27 at 5:26 PM
iCAD Cancer Detecting Product Gets FDA Premarket OKiCAD Cancer Detecting Product Gets FDA Premarket OK
www.investopedia.com - March 27 at 5:26 PM
ICAD INC Files SEC form 10-K, Annual ReportICAD INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 24 at 5:53 PM
iCADs (ICAD) CEO Ken Ferry on Q4 2016 Results - Earnings Call TranscriptiCAD's (ICAD) CEO Ken Ferry on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 9 at 8:55 PM
ICAD INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsICAD INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 9 at 8:55 PM
Q4 2016 ICAD Inc Earnings Release - After Market CloseQ4 2016 ICAD Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 8 at 11:36 PM
Icad reports 4Q lossIcad reports 4Q loss
www.cnbc.com - March 8 at 6:36 PM
ICAD INC Files SEC form 8-K, Completion of Acquisition or Disposition of AssetsICAD INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets
biz.yahoo.com - February 8 at 6:33 PM
ICAD INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsICAD INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
us.rd.yahoo.com - December 22 at 11:07 PM
2:12 pm iCAD discloses that Invivo Corp purchased all right, title, & interest to certain intellectual property relating to the VersaVue Software, the DynaCAD product, & related assets for about $3.2 mln2:12 pm iCAD discloses that Invivo Corp purchased all right, title, & interest to certain intellectual property relating to the VersaVue Software, the DynaCAD product, & related assets for about $3.2 mln
us.rd.yahoo.com - December 22 at 11:07 PM
BRIEF-Icad says entered into asset purchase agreement with Invivo Corp- SEC filingBRIEF-Icad says entered into asset purchase agreement with Invivo Corp- SEC filing
www.reuters.com - December 22 at 6:06 PM

SEC Filings

iCAD (NASDAQ:ICAD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

iCAD (NASDAQ:ICAD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

iCAD (NASDAQ ICAD) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.